Ophthalmology
Cognition to commence Phase II trial of dry AMD drug candidate
Cognition Therapeutics has announced plans to commence the Phase II MAGNIFY clinical trial of its oral drug candidate, CT1812, for…
ONL Therapeutics closes first tranche of financing for trial of ONL1204
ONL Therapeutics has closed on the first $15m Series C financing tranche to support the advancement of ONL1204 Ophthalmic Solution…
Pipeline Moves: advancement prospects slump for lupus drug after negative topline data
This week on Pipeline Moves, we start by looking at the negative topline results from a Phase II systemic lupus…
Ocugen files IND application with US FDA for Phase I DME trial
Ocugen has announced the submission of an investigational new drug (IND) application with the US Food and Drug Administration (FDA)…
HuidaGene receives FDA clearance for retinal dystrophies therapy trial
HuidaGene Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application…
Pipeline Moves: Novartis completes ulcerative colitis trial, advancement prospects rise
This week on Pipeline Moves, we start with the completion of Novartis’s Phase II trial in ulcerative colitis. We also…
Pipeline Moves: approval prospects jump for AstraZeneca’s breast cancer drug
This week on Pipeline Moves, we look into the announcements of positive data from two Phase III trials in breast…
Roche reports positive data from Phase III retinal vein occlusion trials
Roche has reported positive topline data from two Phase III clinical trials of a bispecific antibody, Vabysmo (faricimab), to treat…
LENZ reports positive findings from Phase II presbyopia treatment trial
LENZ Therapeutics has reported positive topline data from its Phase II INSIGHT clinical trial of two investigational aceclidine formulations for the treatment…
Pipeline Moves: trial completions in glaucoma, lung, and oncology indications
This week on Pipeline Moves, we look into the completion of a Phase III trial in open-angle glaucoma. For Phase…